ArticleImmunity, inflammation and disease2026
Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS-Mediated Ferroptosis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS-Mediated Ferroptosis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) possess immunoregulatory properties and have been shown to alleviate symptoms of Crohn's disease (CD). While ferroptosis has been implicated in the onset of CD, the precise connection between MSCs, CD, and ferroptosis remains unclear. This study sought to explore whether MSCs could alleviate CD by inhibiting ferroptosis. MATERIALS AND
methodsWe screened the hub genes involved in both ferroptosis and CD and validated them in clinical colon biopsies by immunohistochemistry (IHC). MSCs were administered intraperitoneally to mice with colitis induced by trinitrobenzene sulfonic acid (TNBS) enema to evaluate the therapeutic effect. Additionally, a rescue experiment was conducted by co-treating colitis mice with a cystathionine-β-synthase (CBS) inhibitor (aminooxyacetic acid, AOAA) and MSCs to further explore the mechanism of the MSCs-CBS-ferroptosis axis. The expression levels of CBS and ferroptosis-related markers in colonic tissues were assessed by real-time quantitative polymerase chain reaction (RT-qPCR), western blot, and IHC.
resultsBioinformatics and machine learning identified CBS as a hub gene in both CD and ferroptosis. IHC revealed that CBS expression was downregulated in colon tissues from CD patients. MSCs treatment significantly reduced pathological symptoms and intestinal inflammation in colitis mice. MSCs increased CBS expression, which had been diminished in colitis mice. Additionally, MSCs increased glutathione (GSH) and glutathione peroxidase 4 (GPX4) expression, thereby inhibiting ferroptosis activation. In a rescue experiment, co-treatment with AOAA and MSCs exacerbated intestinal inflammation and reversed the elevation of CBS and ferroptosis-related markers. DISCUSSION: This study demonstrates that MSCs alleviate the symptoms of CD by regulating CBS-mediated ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.